ALLO

Allogene Therapeutics, Inc. develops allogeneic CAR T cell therapies designed to treat cancer. Headquartered in South San Francisco, California, the clinical-stage biotechnology company focuses on creating off-the-shelf treatments that can be manufactured at scale, contrasting with traditional autologous CAR T therapies that require individual patient customization. The company's pipeline includes ALLO-501A and ALLO-715, targeting hematologic malignancies such as large B-cell lymphoma and multiple myeloma, alongside programs for solid tumors. Allogene employs TALEN gene-editing technology licensed from Cellectis to eliminate T-cell receptors and reduce rejection risk in allogeneic treatments. Founded in 2017 through a collaboration with Servier, Allogene secured exclusive rights to develop and commercialize Servier's allogeneic CAR T portfolio. The company operates manufacturing facilities to support its clinical trials and future commercial production. Allogene trades on the Nasdaq under the ticker symbol ALLO and maintains partnerships with institutions including Pfizer and the University of California, San Francisco. Recent developments include advancing multiple Phase 1 and Phase 2 clinical trials evaluating its product candidates across various cancer indications. As of its latest reports, the company employs approximately 500 people and remains in the pre-revenue stage, funding operations primarily through equity financings while working toward regulatory approvals for its investigational therapies.